A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation

The purpose of this study is to evaluate the relative bioavailability of VX‐581 tabletformulation compared to a suspension formulation along with its safety and tolerabilityin healthy human participants. Note: This clinical trial information was submittedvoluntarily under the applicable law and, therefore, certain submission deadlines may notapply. (That is, clinical trial information for this applicable clinical trial wassubmitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60and is not subject to the deadlines established by sections 402(j)(2) and (3) of thePublic Health Service Act or 42 CFR 11.24 and 11.44.).